CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03219268
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:24.071009+00:00
Published At: 2023-12-21T00:00:00+00:00
Record Updated At: 2023-12-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Solid Tumors", "Hematologic Neoplasms", "Ovarian Cancer", "HER2-positive Advanced Solid Tumors", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Cholangiocarcinoma", "Cervical Cancer", "TNBC - Triple-Negative Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-21"
protocolSection.identificationModule.nctId: "NCT03219268"
protocolSection.identificationModule.officialTitle: "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART\u00ae Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.